The current understanding of the mechanism of anti-tuberculosis drug resistance has been
shaped by the history of development of anti-tuberculosis drugs in the past 60 years and …

Current tuberculosis (TB) therapies take too long and the regimens are complex and subject
to adverse effects and drug–drug interactions with concomitant medications. The emergence …

Background Tuberculosis (TB) is a global health challenge and one of the leading causes of
death worldwide. In the last decade, the TB treatment landscape has dramatically changed …

Current tuberculosis (TB) treatment is based on a combination of drugs that were developed
mostly in the central decades of the last century. Cure rates are high for drug sensitive …

Tuberculosis (TB) has been a transmittable human disease for many thousands of years,
and M. tuberculosis is again the number one cause of death worldwide due to a single …

Anti‐tuberculosis (TB) drugs possess diverse abilities to penetrate the different host tissues
and cell types in which infecting Mycobacterium tuberculosis bacilli are located during active …

New drugs that retain potency against multidrug/extensively drug-resistant strains of
Mycobacterium tuberculosis, with the additional benefit of a shortened treatment duration …

Accelerating the transition of new tuberculosis drug combinations from Phase II to Phase III
trials: New technologies and innovative designs | PLOS Medicine Skip to main content …

Novel treatment strategies for tuberculosis are urgently needed. Many different preclinical
models assessing anti-tuberculosis drug activity are available, but it is yet unclear which …

Several infectious diseases of global importance—eg, HIV infection and tuberculosis (TB)—
require prolonged treatment with combination antimicrobial regimens typically involving high …